L-PGDS is a promising urinary biomarker of active LN, especially for its ability to predict renal disease activity and identify potential non-responders to therapy, although its lack of specificity for JSLE may hinder its clinical applications in patients with other comorbidities, such as diabetes or hypertension. Here, PTGDS is linked to lobular neoplasia.